Advertisement
Other members returning to Lorus' Board are Herbert Abramson, Chairman andCEO of Trapeze Capital Corp.; J. Kevin Buchi, EVP and CFO of Cephalon Inc.;Georg Ludwig, Managing Director of ConPharm Anstalt; Alan A. Steigrod,Managing Director of Newport Healthcare Ventures; Dr. Jim A. Wright, CEO ofNuQuest Bio Inc.; and Dr. Aiping Young, President and CEO of LorusTherapeutics Inc.
Advertisement
Denis R. Burger
Dr. Denis R. Burger has co-founded Trinity Biotech plc, based in Dublin,Ireland in June 1992 and acted as Chairman from 1992 to 1995 and now serves onthe Board of Directors of the Company. Dr. Burger was the past Chairman, ChiefExecutive Officer and a director of AVI Biopharma Inc, an Oregon basedbiotechnology company. Dr. Burger is also a partner in Sovereign Ventures, ahealthcare consulting and funding firm based in Portland, Oregon. He was aco-founder and, from 1981 to 1990, Chairman of Epitope Inc. In addition, Dr.Burger has held a professorship in the Department of Microbiology andImmunology and Surgery (Surgical Oncology) at the Oregon Health SciencesUniversity in Portland. Dr. Burger received his Master of Science and PhD inMicrobiology and Immunology from the University of Arizona.
Susan Koppy
Susan Koppy is the senior vice president, business and corporatedevelopment of Idenix Pharmaceuticals since January 2006. Prior to joiningIdenix, Ms. Koppy was with Applied Biosystems, Inc. as vice president ofstrategy and business development from May 2004 to July 2005. Previously, from2001-2004, Ms. Koppy served as director of business development for NovartisPharmaceuticals AG focusing on its Infectious Diseases Franchise. Prior tothat, since February 2000, Ms. Koppy was Novartis' head of commercial andbusiness intelligence.
Mark Vincent
Dr. Mark Vincent is the co-founder and Chief Executive Officer of Sarissa,Inc. since 2000. Dr. Vincent has extensive experience as a consultant toCanadian and U.S. biotech and pharma companies. He served as a Director ofDrug Royalty Corporation and also sits as a member of Scientific AdvisoryBoard for several biotechnology companies. Dr. Vincent is an AssociateProfessor of Oncology at the University of Western Ontario and a staff medicaloncologist at the London Regional Cancer Program.
"On behalf of the Board of Directors, I am delighted to welcome thesethree talented and highly qualified individuals to our Board. They all bringto Lorus an exceptional level of knowledge and experience in thepharmaceutical industry, which will contribute to the advancement of our drugcandidates", commented Dr. Aiping Young, President and CEO of Lorus. "Thenewly-appointed Directors will provide expertise in areas of clinicaldevelopment; facilitating investment and strategic partnering opportunities;and raising the profile of the Company nationally and internationally. I lookforward to the input of all of our Board members and working with them, toenhance shareholder value."
About Lorus
Lorus is a biopharmaceutical company focused on the research anddevelopment of novel therapeutics in cancer. Lorus' goal is to capitalize onits research, preclinical, clinical and regulatory expertise by developing newdrug candidates that can be used, either alone, or in combination with otherdrugs, to successfully manage cancer. Through its own discovery efforts and anacquisition and in-licensing pro
